Evaxion A/S’s (EVAX) Buy Rating Reiterated at HC Wainwright

Evaxion A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $16.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 396.89% from the company’s current price.

Several other research firms also recently commented on EVAX. Maxim Group started coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Evaxion A/S has a consensus rating of “Moderate Buy” and an average price target of $11.75.

Evaxion A/S Trading Down 5.3%

Shares of NASDAQ:EVAX opened at $3.22 on Monday. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. Evaxion A/S has a 52-week low of $1.20 and a 52-week high of $12.15. The stock has a market cap of $26.85 million, a price-to-earnings ratio of -2.44 and a beta of 0.28. The business has a 50-day moving average price of $3.90 and a 200-day moving average price of $4.63.

Evaxion A/S (NASDAQ:EVAX) last issued its earnings results on Thursday, March 5th. The company reported $0.30 EPS for the quarter. Equities analysts predict that Evaxion A/S will post -0.15 EPS for the current year.

Hedge Funds Weigh In On Evaxion A/S

Several institutional investors have recently made changes to their positions in the company. Wesbanco Bank Inc. acquired a new position in shares of Evaxion A/S in the 4th quarter valued at $48,000. SmartHarvest Portfolios LLC purchased a new position in Evaxion A/S in the fourth quarter valued at $72,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S in the fourth quarter worth about $38,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.